Skip to main content

A multi-parametric Regulatory T cell Atlas in cancer to predict immunotherapy response, adverse autoimmune events and to identify novel therapeutic targets

Project description

Regulatory T cell based predictive biomarkers of cancer immunotherapy response

The advent of immune checkpoint inhibitors (ICI) targeting regulatory pathways in T cells to ignite antitumour immune responses has revolutionised cancer immunotherapy. However, a significant proportion of patients do not develop a response, or it is accompanied by life-threatening autoimmunity, manifesting as immune-related adverse events (irAEs). Predictive biomarkers of clinical responses and new therapeutic strategies to harness antitumour immunity represent an urgent unmet need. The regulatory T cells (Tregs) are a subpopulation of T cells that modulate the immune system responses. The EU-funded RegSign project will create a 'liquid biopsy' of Tregs for the prediction of ICI efficacy and development of irAEs. Decoding Tregs' signatures in cancer will lead to predictive biomarkers and novel targets for cancer immunotherapy.

Host institution

IDRYMA IATROVIOLOGIKON EREUNON AKADEMIAS ATHINON
Net EU contribution
€ 1 500 000,00
Address
Soranou Efesiou 4
115 27 Athina
Greece

See on map

Region
Κεντρικός Τομέας Αθηνών Aττική Αττική
Activity type
Research Organisations
Other funding
€ 1 500 000,00

Beneficiaries (1)

IDRYMA IATROVIOLOGIKON EREUNON AKADEMIAS ATHINON
Greece
Net EU contribution
€ 1 500 000,00
Address
Soranou Efesiou 4
115 27 Athina

See on map

Region
Κεντρικός Τομέας Αθηνών Aττική Αττική
Activity type
Research Organisations
Other funding
€ 1 500 000,00